Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
April 14, 2016 12:07 PM EDTIn addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier, Leerink analyst Joseph Schwartz listed 9 other stocks on his Top 10 list. Below is a run-down of the others:
Akorn, Inc. (NASDAQ: AKRX) (Market Perform)
Rationale for P&A: "AKRX operates in generic segments with higher barriers... More
Acadia Pharma (ACAD) Higher as Leerink Highlights as Partnership and Acquisition Target
April 14, 2016 9:57 AM EDTAcadia Pharma (NASDAQ: ACAD) is solidly higher early Thursday (+3.2%) after Leerink Partners analyst Joseph Schwartz highlighted the company as one his Top Ten partnership and acquisition (P&A) stocks in biophama.
Commenting on the rationale for P&A, he said:
"Recent positive... More
